Real-world treatment patterns and outcomes among patients (pts) with second-line (2L) and third-line (3L) metastatic triple-negative breast cancer (mTNBC) in England using the Cancer Analysis System (CAS).

被引：0
|
作者：
Chang, Lawrence
Hall, Peter S.
Preger, Luciana
Sjekloca, Nikoleta
Bergamaco, Estevan
Broe, Anne
Petrova, Plamena
Berg, Paul
Reich, Adam
Pawar, Neha
Gharaibeh, Mahdi
机构：
[1] Gilead Sci Inc, Foster City, CA USA
[2] Univ Edinburgh, Inst Genet & Canc, Edinburgh, Scotland
[3] Genentech Inc, South San Francisco, CA USA
[4] IQVIA, London, England
[5] IQVIA, Sofia, Bulgaria
[6] IQVIA, La Crosse, WI USA
[7] IQVIA, Gurgaon, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1075
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Metastatic triple-negative Breast Cancer (mTNBC) - Second-line Therapy mTNBC: Sacituzumab Govitecan with high Effectiveness even in HER2-low
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (7-8) : 343 - 343
  • [22] LONG TERM SAFETY OF CONVENTIONAL AND BIOLOGIC IL-6RI IMMUNOMODULATORS AS SECOND-LINE (2L) OR THIRD-LINE (3L) TREATMENT OF POLYMYALGIA RHEUMATICA
    Dikranian, A.
    Calabrese, C.
    Bingham, C.
    Fiore, S.
    Ford, K.
    Araujo, L.
    Xie, F.
    Curtis, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1556 - 1557
  • [23] Patterns and predictors of first-line (1L) taxane use in US patients with metastatic triple-negative breast cancer (mTNBC)
    O'Shaughnessy, J.
    Emens, L. A.
    Chui, S.
    Russell, K.
    Lin, S. -W.
    Avile, C. Flores
    Luhn, P.
    Schneeweiss, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 131 - 131
  • [24] Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada
    Gambaro, Karen
    Groleau, Melanie
    Mcnamara, Suzan
    Awan, Arif
    Salem, Maged
    Abdelsalam, Mahmoud
    St-Hilaire, Eve
    Vincent, Francois
    Carrier, Julie
    Mackay, Helen
    Provencher, Louise
    Boudreau, Dominique
    Hamilou, Zineb
    Saad, Fred
    Ferrario, Cristiano
    Batist, Gerald
    Marques, Maud
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2023, 26 : 12078
  • [25] A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer
    Shao, Yingbo
    Luo, Zhifen
    Yu, Yang
    He, Yaning
    Liu, Chaojun
    Chen, Qi
    Zhu, Fangyuan
    Nie, Bing
    Liu, Hui
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [26] Real-world data comparing third and subsequent line regimens for treatment of metastatic triple-negative breast cancer in the United States.
    Aran, Dvir
    Klein-Brill, Avital
    Fisch, Michael Jordan
    Amar-Farkash, Shlomit
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18765 - E18765
  • [27] Real-world treatment patterns and outcomes among elderly metastatic triple negative breast cancer patients in the United States
    Satram-Hoang, S.
    Bajaj, P.
    Stein, A.
    Hoang, K. Q.
    Momin, F.
    Cortazar, P.
    Reyes, C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC)
    Ahn, D.
    Park, N. J.
    Locker, M. C.
    Zhou, Z-Y.
    Nie, X.
    Wang, T.
    Yu, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S613 - S613
  • [29] Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
    Lisa A. Carey
    Delphine Loirat
    Kevin Punie
    Aditya Bardia
    Véronique Diéras
    Florence Dalenc
    Jennifer R. Diamond
    Christel Fontaine
    Grace Wang
    Hope S. Rugo
    Sara A. Hurvitz
    Kevin Kalinsky
    Joyce O’Shaughnessy
    Sibylle Loibl
    Luca Gianni
    Martine Piccart
    Yanni Zhu
    Rosemary Delaney
    See Phan
    Javier Cortés
    npj Breast Cancer, 8
  • [30] COST-EFFECTIVENESS ANALYSIS OF SACITUZUMAB GOVITECAN AS SECOND-LINE TREATMENT FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER IN JAPAN
    Yamaguchi, M.
    Maeda, T.
    Morimoto, K.
    Chen, W.
    Moriwaki, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2023, 26 (06) : S106 - S106
12345